Markets

BioCardia misses beat; postpones $50 million IPO

BioCardia, which is developing regenerative medicine for heart failure based a patient's own bone marrow, postponed its IPO on Tuesday.

The company had intended to raise $50 million by offering 3.85 million shares at a proposed price range of $12 to $14.

The San Carlos, CA-based company was founded in 2002 and had planned to list on the Nasdaq under the symbol BCDA. Cantor Fitzgerald, Roth Capital and Maxim Group LLC were set to be the joint bookrunners on the deal.

The article BioCardia misses beat; postpones $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BCDA

Other Topics

IPOs

Latest Markets Videos